Evidence map›Paper›PMID 33729002›Full record

ArticleIntegrative cancer therapies

Differential Effects of

Li-Jeng Chen, Tsai-Ching Hsu, Pei-Jung Yeh, Jia Le Yow, Chia-Ling Chang, Cheng-Hui Lin, Bor-Show Tzang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Ethnobotanical Survey on Bitter Tea in Taiwan.Frontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Li-Jeng ChenInstitute of Medicine, Chung Shan Medical University, Taichung City, Taiwan, R.O.C.ORCID 0000-0002-0043-6248
Tsai-Ching HsuInstitute of Medicine, Chung Shan Medical University, Taichung City, Taiwan, R.O.C.
Pei-Jung YehInstitute of Medicine, Chung Shan Medical University, Taichung City, Taiwan, R.O.C.
Jia Le YowInstitute of Medicine, Chung Shan Medical University, Taichung City, Taiwan, R.O.C.
Chia-Ling ChangDepartment of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung City, Taiwan, R.O.C.
Cheng-Hui LinDivision of Rheumatology Immunology Clinic, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung City, Taiwan, R.O.C.
Bor-Show TzangInstitute of Medicine, Chung Shan Medical University, Taichung City, Taiwan, R.O.C.ORCID 0000-0003-0140-9943
Chung Shan Medical University · TWChung Shan Medical University Hospital · TWKaohsiung Armed Forces General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGlioblastoma multiforme (GBM) is the most aggressive glioma, and its diffuse nature makes resection of it difficult. Moreover, even with the administration of postoperative radiotherapy and chemotherapy, prolonged remission is often not achieved. Hence, innovative or alternative treatments for GBM are urgently required. Traditional Chinese herbs and their functional components have long been used in the treatment of various cancers, including GBM. The current study investigated the antitumor activity of MATERIALS AND

methodsMTT assay, Transwell migration assay, and flow cytometry analysis were adopted to assess the cell viability, invasive capability, and cell cycle. Immunofluorescence staining and Western blotting were used to detect the expressions of apoptotic and autophagy-related signaling molecules.

resultsThe

conclusionsTaken together, these findings indicate the potential of using WCE and the combination of luteolin and apigenin for GBM treatment. However, further investigations are warranted before considering recommending the clinical use of WCE or the combination of luteolin and apigenin as the standard for GBM treatment.

Indexed as

Brain NeoplasmsGlioblastomaWedeliaApoptosisCell Line, TumorCell ProliferationHumansapoptosisautophagyglioblastoma multiformetraditional Chinese medicineWedelia chinensis extract

Identifiers

PMID33729002
PMCPMC7983241
OpenAlexW3138179433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.